Meeting Summary

Alabama Medicaid Agency
Pharmacy and Therapeutics (P&T) Committee

November 4, 2020

Members Present: Dr. Lee Carter (Vice-Chairperson), Dr. Kimberly Graham, Dr. Albert Holloway, Dr. Frances Heinze (Chairperson), Dr. Peter Hughes, Dr. Charles Nevels, Dr. Kelli Littlejohn Newman, and Dr. Melinda Rowe

Members Absent: None

Presenters: Dr. Thomas Pomfret and Dr. Warren Smith

Chairperson Heinze called the Pharmacy and Therapeutics (P&T) Committee Meeting to order at 9:06 a.m. The minutes from the August 5, 2020 P&T Committee Meeting were approved with no objections. There was no old business.

Pharmacy Program Update:
Dr. Newman discussed that the Agency is finalizing the budget for 2022 and working diligently to determine the COVID impact. The Agency is anticipating an announcement for the public health emergency to be extended another month.

Pharmacotherapy Class Re-reviews (Please refer to the website for full text reviews.)
University of Massachusetts Medical School Clinical Pharmacy Services presented 10 drug class reviews. The Alzheimer’s Agents, Antidepressants, Cerebral Stimulants/Agents Used for ADHD, Wakefulness Promoting Agents, Anxiolytics, Sedatives, and Hypnotics – Barbiturates, Anxiolytics, Sedatives, and Hypnotics – Benzodiazepines, Anxiolytics, Sedatives, and Hypnotics – Miscellaneous, Genitourinary Smooth Muscle Relaxants: Antimuscarinics, Genitourinary Smooth Muscle Relaxants: Beta-3 Agonists, and Disease-Modifying Antirheumatic Agents were last reviewed in August 2018. There was one new drug review: Vumerity® (diroximel fumarate).

A. For the following therapeutic classes, it was determined that all brand products within the class reviewed were comparable to each other and to the generic products in the class (if applicable) and offer no significant clinical advantage over other alternatives in general use.
   • Alzheimer’s Agents: Parasympathomimetic (Cholinergic) Agents, AHFS 120400; and Central Nervous System Agents, Miscellaneous, AHFS 289200
   • Antidepressants: AHFS 281604
   • Cerebral Stimulants/Agents Used for ADHD: Central Alpha-Agonists, AHFS 240816; Amphetamines, AHFS 282004; Respiratory and CNS Stimulants, AHFS Class 282032; and Central Nervous System Agents, Miscellaneous, AHFS 289200
   • Wakefulness Promoting Agents: AHFS 282080
   • Anxiolytics, Sedatives, and Hypnotics-Barbiturates: AHFS 282404
• Anxiolytics, Sedatives, and Hypnotics-Benzodiazepines: AHFS 282408
• Anxiolytics, Sedatives, and Hypnotics-Miscellaneous: AHFS 282492
• Genitourinary Smooth Muscle Relaxants, Antimuscarinics: AHFS 861204
• Genitourinary Smooth Muscle Relaxants, Beta-3-Adrenergic Agonists: AHFS 861208
• Disease-Modifying Antirheumatic Agents: AHFS 923600
• New Drug Review Vumerity® (diroximel fumarate): AHFS 922000

**Recommendation:** No brand agent is recommended for preferred status. Alabama Medicaid should accept cost proposals from manufacturers to determine the most cost effective products and possibly designate one or more preferred brands.

For the antidepressant pharmacotherapy class re-review only, no brand monoamine oxidase inhibitor is recommended for preferred status, regardless of cost.

**Amendment:** None

**Vote:** Unanimous to approve as recommended

---

**Miscellaneous Items:**

Dr. Heinze has been voted to be the Vice-Chair and Dr. Carter will move to the Chair position. The next P&T Committee Meeting is scheduled for February 3, 2021. There being no further business, Dr. Carter moved to adjourn, and Dr. Hughes seconded. The meeting adjourned at 10:05 a.m.

Respectfully submitted,

[Signature]

11/04/2020

Thomas C. Pomfret, PharmD, MPH, BCPS

[Signature]

11/04/2020

Rachel Bacon, PharmD